A detailed history of Morgan Stanley transactions in Harrow Health, Inc. stock. As of the latest transaction made, Morgan Stanley holds 952,523 shares of HROW stock, worth $17.1 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
952,523
Previous 1,366,741 30.31%
Holding current value
$17.1 Million
Previous $15.3 Million 17.68%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$9.3 - $13.23 $3.85 Million - $5.48 Million
-414,218 Reduced 30.31%
952,523 $12.6 Million
Q4 2023

Feb 13, 2024

SELL
$8.1 - $16.36 $3.33 Million - $6.72 Million
-410,920 Reduced 23.12%
1,366,741 $15.3 Million
Q3 2023

Nov 15, 2023

BUY
$14.03 - $22.08 $117,346 - $184,677
8,364 Added 0.47%
1,777,661 $25.5 Million
Q2 2023

Aug 14, 2023

BUY
$17.37 - $28.08 $14.2 Million - $23 Million
818,467 Added 86.08%
1,769,297 $33.7 Million
Q1 2023

May 15, 2023

BUY
$13.84 - $21.46 $12.7 Million - $19.8 Million
920,669 Added 3052.51%
950,830 $20.1 Million
Q4 2022

Feb 14, 2023

BUY
$10.28 - $14.78 $188,792 - $271,434
18,365 Added 155.69%
30,161 $445,000
Q3 2022

Nov 14, 2022

SELL
$6.57 - $24.88 $82,289 - $311,622
-12,525 Reduced 51.5%
11,796 $142,000
Q2 2022

Oct 27, 2022

SELL
$5.75 - $7.74 $103,448 - $139,250
-17,991 Reduced 42.52%
24,321 $177,000
Q2 2022

Aug 15, 2022

SELL
$5.75 - $7.74 $103,448 - $139,250
-17,991 Reduced 42.52%
24,321 $177,000
Q1 2022

Oct 27, 2022

BUY
$6.77 - $8.66 $121,799 - $155,802
17,991 Added 73.97%
42,312 $289,000
Q1 2022

May 13, 2022

SELL
$6.77 - $8.66 $257,774 - $329,738
-38,076 Reduced 47.37%
42,312 $289,000
Q4 2021

Feb 14, 2022

SELL
$8.5 - $12.0 $39,125 - $55,236
-4,603 Reduced 5.42%
80,388 $695,000
Q3 2021

Nov 15, 2021

BUY
$6.99 - $10.6 $594,087 - $900,904
84,991 New
84,991 $773,000

Others Institutions Holding HROW

About HARROW HEALTH, INC.


  • Ticker HROW
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 27,070,000
  • Market Cap $486M
  • Description
  • Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company tha...
More about HROW
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.